Journals / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 3

Investigation of PhiKZ phage therapy against Pseudomonas aeruginosa in mouse pneumonia model

Pages
670–678
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study might have proved communication between lungs and kidneys related to proinflammatory cytokines.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: The aim of this study was to investigate the effects of PhiKZ phage therapy and meropenem alone or combinedtreatments in a pneumonia mouse model induced by the Pseudomonas aeruginosa PAO1 strain.
📊
Key Findings & Data:The cross-talk between lungs andkidneys was also determined.Materials and methods: The systemic, lung-specific, and kidney-specific inflammation levels and the bacterial load in lung tissue andbiochemical parameters were investigated after PhiKZ phage therapy and meropenem alone or combined treatments in a pneumoniamouse model induced by the P. aeruginosa PAO1 strain.
💡
Conclusion & Impact:This study might have proved communication between lungs and kidneys related to proinflammatory cytokines.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: The aim of this study was to investigate the effects of PhiKZ phage therapy and meropenem alone or combinedtreatments in a pneumonia mouse model induced by the Pseudomonas aeruginosa PAO1 strain. The cross-talk between lungs andkidneys was also determined.Materials and methods: The systemic, lung-specific, and kidney-specific inflammation levels and the bacterial load in lung tissue andbiochemical parameters were investigated after PhiKZ phage therapy and meropenem alone or combined treatments in a pneumoniamouse model induced by the P. aeruginosa PAO1 strain. The cross-talk between lungs and kidneys was also determined by measuringplasma levels of glycocalyx components.Results: The greatest reduction in lung bacterial load was obtained with the combined use of the PhiKZ phage and meropenem. TheC-reactive protein level in the patient group was significantly higher than in the treatment groups and decreased after treatment. Seruminterleukin IL-6 levels were statistically significantly higher than in the phage serum and phage + meropenem groups. Pulmonaryinfection can trigger proinflammatory cytokines such as IL-6, TNF-α, and IL-1β. Increased cytokines trigger insulin resistance in theliver. Lung infection triggers liver inflammation because there is communication between the lungs and liver.Conclusion: Elevated proinflammatory cytokines due to infection were decreased because of the reduced burden of bacterial load aftertreatment. This study might have proved communication between lungs and kidneys related to proinflammatory cytokines.

🔖

Cite This Article

AKSU, U., CAN, K., YENEN, O. Ş. (2022). Investigation of PhiKZ phage therapy against Pseudomonas aeruginosa in mouse pneumonia model. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 3, 670–678. https://ajindex.com/articles/610326

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Weber-Dabrowska B, Jonczyk-Matysiak E, Zaczek M, Lobocka M, Lusiak-Szelachowska M, Gorski A. Bacteriophage procurement for therapeutic purposes. Frontiers in Microbiology 2016; 7: 1177. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechno 2010; 11: 28-47.
  2. Ross A, Ward S, Hyman P. More is better: selecting for broad host range bacteriophages. Front Microbiol 2016; 7: 1352. Sulkin SE, Douglass DD, Bronfenbrenner J. Bacteriophage therapy. IV. Effect of bacteriophage in experimental staphylococcal septicemia in rabbits. J Infect Dis 1942; 70: 92- 95. Bronfenbrenner J, Sulkin SE. Bacteriophage therapy: III. On the nature of the deleterious effect of the local application of staphylococcus bacteriophage. J Infect Dis 1939; 65: 64-72.
  3. Bronfenbrenner J, Sulkin SE. Prophylactic and therapeutic effect of bacteriophage and of antivirus in experimental staphylococcus infection of the eye. Am J Ophthalmol 1939; 22: 1321-1325.
  4. Salmond GP, Fineran PC. A century of the phage: past, present and future. Nat Rev Microbiol 2015; 13: 777-786.
  5. Gill JJ, Hyman P. Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechno 2010; 11: 2-14. D’Agata E. Pseudomonas aeruginosa and other Pseudomonas species. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA, USA: Saunders; 2015. pp. 2518-2531.
  6. Morita Y, Tomida J, Kawamura Y. Responses of Pseudomonas aeruginosa to antimicrobials. Front Microbiol 2014; 4: 422. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechno 2010; 11: 69-86.
  7. Yakunina M, Artamonova T, Borukhov S, Makarova KS, Severinov K, Minakhin L. A non-canonical multisubunit RNA polymerase encoded by a giant bacteriophage. Nucleic Acids Res 2015; 43: 10411-10420.
  8. Mesyanzhinov VV, Robben J, Grymonprez B, Kostyuchenko VA, Bourkaltseva MV, Sykilinda NN, Krylov VN, Volckaert G. The genome of bacteriophage φKZ of Pseudomonas aeruginosa. J Mol Biol 2002; 317: 1-19.
  9. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011; 1: 66-85. Abedon ST. Phage therapy: eco-physiological pharmacology. Scientifica 2014; 2014: 581639. Morrison S, Gardner RE. The treatment of a lung abscess due to Bacillus coli with a lytic filtrate. J Amer Med Assoc 1936; 107: 33-34. Abedon ST. Phage therapy of pulmonary infect